theory clinical_1_3
imports Main

begin

typedecl entity
typedecl event

consts
  Olaparib :: "entity ⇒ bool"
  Rucaparib :: "entity ⇒ bool"
  PARP1Inhibitor :: "entity ⇒ bool"
  LicensedForUseIn :: "entity ⇒ entity ⇒ bool"
  ProstateCancerPatient :: "entity ⇒ bool"
  PotentialTreatmentOption :: "entity ⇒ entity ⇒ bool"
  PatientWithLossOfBRCA2 :: "entity ⇒ bool"
  MechanismOfAction :: "entity ⇒ bool"
  PARP1Inhibition :: "entity ⇒ bool"
  SyntheticLethality :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Source :: "event ⇒ entity ⇒ bool"
  Reason :: "event ⇒ entity ⇒ bool"
  Cause :: "event ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  Rely :: "event ⇒ bool"
  Mechanism :: "event ⇒ bool"
  Repair :: "event ⇒ bool"
  CumulativeDamage :: "entity ⇒ bool"
  ViableTreatmentOption :: "entity ⇒ bool"
  DNA :: "entity"
  TreatmentOption :: "entity ⇒ bool"
  PatientEntity :: "entity ⇒ bool"  (* Renamed to avoid conflict with event-level Patient *)
  Potential :: "entity ⇒ bool"
  For :: "entity ⇒ entity ⇒ bool"

(* Explanation 1: Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients and is a potential treatment option for any patient with loss of BRCA2 due to its mechanism of action. *)
axiomatization where
  explanation_1: "∀x y z. Olaparib x ∧ PARP1Inhibitor x ∧ LicensedForUseIn x y ∧ ProstateCancerPatient y ∧ PotentialTreatmentOption x z ∧ PatientWithLossOfBRCA2 z ∧ MechanismOfAction x"

(* Explanation 2: Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients and is a potential treatment option for any patient with loss of BRCA2 due to its mechanism of action. *)
axiomatization where
  explanation_2: "∀x y z. Rucaparib x ∧ PARP1Inhibitor x ∧ LicensedForUseIn x y ∧ ProstateCancerPatient y ∧ PotentialTreatmentOption x z ∧ PatientWithLossOfBRCA2 z ∧ MechanismOfAction x"

(* Explanation 3: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality, which causes cells to rely on a singular mechanism to repair cumulative damage to DNA, making Olaparib and Rucaparib viable treatment options. *)
axiomatization where
  explanation_3: "∀x y z e1 e2 e3 e4. PatientWithLossOfBRCA2 x ∧ PARP1Inhibition y ∧ SyntheticLethality z ∧ Benefit e1 ∧ Agent e1 x ∧ Source e1 y ∧ Reason e1 z ∧ Cause e2 ∧ Agent e2 z ∧ Patient e2 e3 ∧ Rely e3 ∧ Agent e3 e4 ∧ Mechanism e4 ∧ Repair e4 ∧ Patient e4 DNA ∧ CumulativeDamage DNA ∧ ViableTreatmentOption Olaparib ∧ ViableTreatmentOption Rucaparib"

theorem hypothesis:
  assumes asm: "PatientEntity y"
  (* Hypothesis: There are two potential treatment options for this patient. *)
  shows "∃x. TreatmentOption x ∧ PatientEntity y ∧ Potential x ∧ For x y"
proof -
  (* From the known information, we have a patient entity y. *)
  from asm have "PatientEntity y" <ATP>
  (* Explanation 1 and Explanation 2 provide that Olaparib and Rucaparib are potential treatment options for patients with loss of BRCA2. *)
  (* Explanation 3 states that patients with loss of BRCA2 may benefit from PARP1 inhibition, making Olaparib and Rucaparib viable treatment options. *)
  (* Logical relations Implies(A, C) and Implies(B, D) show that Olaparib and Rucaparib are potential treatment options. *)
  (* Logical relations Implies(E, G) and Implies(F, G) confirm that Olaparib and Rucaparib are viable treatment options. *)
  have "ViableTreatmentOption Olaparib ∧ ViableTreatmentOption Rucaparib" <ATP>
  (* Therefore, there are two potential treatment options for the patient entity y. *)
  then have "∃x. TreatmentOption x ∧ PatientEntity y ∧ Potential x ∧ For x y" <ATP>
  then show ?thesis <ATP>
qed

end
